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Abstract
Background: Human immunodeficiency virus (HIV) is the etiological agent in AIDS and related diseases. The
aspartyl protease encoded by the 5’ portion of the pol gene is responsible for proteolytic processing of the gag-pol
polyprotein precursor to yield the mature capsid protein and the reverse transcriptase and integrase enzymes. The
HIV protease (HIV-1Pr) is considered an attractive target for designing inhibitors which could be used to tackle
AIDS and therefore it is still the object of a number of investigations.
Results: A recombinant human immunodeficiency virus type 1 protease (HIV-1Pr) was overexpressed in Escherichia
coli cells as a fusion protein with bacterial periplasmic protein dithiol oxidase (DsbA) or glutathione S-transferase
(GST), also containing a six-histidine tag sequence. Protein expression was optimized by designing a suitable HIV-
1Pr cDNA (for E. coli expression and to avoid autoproteolysis) and by screening six different E. coli strains and five
growth media. The best expression yields were achieved in E. coli BL21-Codon Plus(DE3)-RIL host and in TB or M9
medium to which 1% (w/v) glucose was added to minimize basal expression. Among the different parameters
assayed, the presence of a buffer system (based on phosphate salts) and a growth temperature of 37°C after
adding IPTG played the main role in enhancing protease expression (up to 10 mg of chimeric DsbA:HIV-1Pr/L
fermentation broth). GST:HIVPr was in part (50%) produced as soluble protein while the overexpressed DsbA:HIV-
1Pr chimeric protein largely accumulated in inclusion bodies as unprocessed fusion protein. A simple refolding
procedure was developed on HiTrap Chelating column that yielded a refolded DsbA:HIV-1Pr with a > 80%
recovery. Finally, enterokinase digestion of resolubilized DsbA:HIV-1Pr gave more than 2 mg of HIV-1Pr per liter of
fermentation broth with a purity ≤ 80%, while PreScission protease cleavage of soluble GST:HIVPr yielded ~ 0.15
mg of pure HIV-1Pr per liter.
Conclusions: By using this optimized expression and purification procedure fairly large amounts of good-quality
HIV-1Pr recombinant enzyme can be produced at the lab-scale and thus used for further biochemical studies.
Background
Retroviral proteins are synthesized as polyprotein pre-
cursors, which are subsequently processed by specific
proteases. The aspartyl protease encoded by the human
immunodeficiency virus (HIV) plays an essential role in
viral maturation and is considered an attractive target
for the treatment of acquired immunodeficiency syn-
d r o m e( A I D S ) .T h eH I V - 1p r o t e a s e( H I V - 1 P r )i s
encoded by the 5’ portion of the pol gene and is respon-
sible for processing the gag and gag-pol polyproteins to
yield mature capsid proteins and the enzymes protease,
reverse transcriptase, and integrase [1].
In the past, HIV-1Pr was synthesized chemically [2] or
expressed by recombinant DNA technology in various
heterologous systems [3]. In order to produce large
amounts of HIV-1Pr, different strategies were investi-
gated: i) it was produced by autocatalytic processing of a
larger precursor [4,5]; ii) it was fused to a variety of pro-
teins, e.g., b-lactamase [6], glutathione S-transferase
(GST), maltose-binding protein [7], N-terminal portion
of g-interferon [8], or as His-tagged recombinant protein
[9]; iii) codon usage, A+T richness at the 5’ end of the
coding region, and the promoter were optimized [10,11];
and iv) it was recovered by refolding of E. coli inclusion
bodies [12,13]. Owing to the cytotoxicity (and low
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any medium, provided the original work is properly cited.solubility) of this protease, it is difficult to obtain it in large
quantities: in most cases the expression level was low and
the recombinant HIV-1Pr could be detected only by
immunoblotting (see Additional file 1, Table S1). After
about 20 years of investigations, HIV-1Pr is still consid-
ered an important target for developing new drugs to cope
with AIDS. Recently, for example, peptides displaying a
sequence identical to thoses e g m e n t so ft h eH I V - 1 P r
monomers associated with the local elementary structures,
LES, have been proposed to destabilize the native structure
o ft h ep r o t e a s e .T h e s en e wi n h i b i t o r sm a yh a v eah i g h
genetic barrier for resistance as they bind HIV-1Pr
through highly conserved residues which play an essential
role in the protein folding process. The properties of pro-
mising inhibitors of HIV-1Pr monomer folding were
investigated with the help of spectrophotometric assays
and circular dichroism spectroscopy [14]. Unfortunately,
these studies require milligram quantities of the viral pro-
tein in the soluble and active form and its commercial
cost represents a main limit for academic studies.
The purpose of this study therefore was to construct a
high and reproducible expression system for HIV-1Pr
and to establish a convenient (simple and fast) purifica-
tion procedure for obtaining fairly large amounts of the
corresponding recombinant active protein at the lab-
scale. In this paper we describe two new methods for
obtaining HIV-1Pr that were established by producing
different chimeric proteins, but also by optimizing both
the expression in E. coli (mainly by acting on host strain
selection and on medium composition) and the purifica-
tion and maturation processes.
Results and Discussion
Expression of DsbA:HIV-1Pr
A synthetic cDNA encoding for a variant HIV-1Pr was
designed to optimize codon usage for protein expression
in E. coli and to avoid autoproteolysis and disulfide
bridge formation (Additional file 1, Figure S1) [15]. Pre-
liminary trials focused on the expression of untagged
HIV-1Pr (by using pET24b(+) and pET26b(+) plasmids):
in no case was HIV-1Pr expressed to a detectable level
(see Additional file 1, Supplementary text).
The synthetic cDNA was then cloned in pET39b(+)
plasmid. In this way, a chimeric protein could be pro-
duced that was constituted by the target protease fused
with the full-length E. coli periplasmic dithiol-oxidase
DsbA protein (Additional file 1, Figure S1A). Under
standard conditions - i.e., BL21(DE3)pLysS cells induced
at the early-exponential phase of growth and cell recov-
ery after 1 hour of incubation at 37°C after adding IPTG
- approx. 0.7 mg of DsbA:HIV-1Pr is produced per liter
of fermentation broth.
Expression trials were then carried out in LB medium
containing 1% (w/v) glucose, growing the cells at 37°C
and using different E. coli strains: BL21(DE3)pLysS,
BL21-Codon Plus(DE3)-RIL, BL21-Star(DE3), C41(DE3),
C41(DE3)pLysS, C43(DE3), C43(DE3)pLysS, and KRX
(Figure 1) [16,17]. The BL21-Codon Plus(DE3)-RIL
strain supplies extra copies of tRNA genes that are rare
in E. coli; the BL21-Star(DE3) host strain allows good
basal expression of the heterologous genes, mainly
because of an increased stability of mRNA molecules,
while C41, C43, and KRX E. coli strains are suitable for
toxic heterologous protein expression because of a resis-
tance to toxic proteins (C41 and C43 strains) or of a
very stringent control of basal expression (KRX strain)
[16,17]. At the same time, the effect of the time point of
protein induction was also investigated by adding IPTG
at the early-, middle-exponential, or stationary growth
Figure 1 Western blot analysis of DsbA:HIV-1Pr protein
expression on total cell extracts of different E. coli strains
containing the pET39-DsbA:HIV-1Pr plasmid. As detected using
anti-His-tag-specific antibodies. Cells were grown in LB medium at
37°C, protein expression was induced using 1 mM IPTG at early-
exponential phase, and cells were harvested after 1 hour. E. coli
strains are: 1: BL21(DE3)pLysS; 2: C41(DE3); 3: C43(DE3); 4: C41(DE3)
pLysS; 5: C43(DE3)pLysS; 6: KRX; 7: BL21-CodonPlus(DE3)-RIL; and 8:
BL21(DE3)Star. In all cases variability among replicate cultures was
lower than 10%. The amount of cells corresponding to 1 mL of
culture was loaded in each lane. St: 0.5 μg of His-tagged
recombinant D-amino acid oxidase.
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antibodies on total cell extracts showed the highest
DsbA:HIV-1Pr expression level for the BL21-Codon
Plus(DE3)-RIL strain (Figure 1) and when IPTG was
added at the middle-exponential phase of growth (see
results in Figure 2B and 2D). Substantial expression of
DsbA:HIV-1Pr chimeric protein was also observed by
inducing protein synthesis at the early-exponential
phase of growth, whereas no HIV-1Pr-associated signal
was observed by adding IPTG at the stationary phase
(Figure 2). In all cases, the recombinant fusion protein
largely accumulated as inclusion bodies: a semi-quanti-
tative analysis carried out by means of Western blot on
the soluble fraction and the cell pellets estimated that ~
80% of the expressed fusion protein is present in the
insoluble fraction (see Figure 3A for cells grown in TB
medium). On the basis of these results, subsequent
investigations were carried out to optimize DsbA:HIV-
1Pr expression using the BL21-Codon Plus(DE3)-RIL E.
coli strain.
At first, the effect of cultivation medium composition
both on the growth of recombinant BL21-Codon Plus
(DE3)-RIL cells carrying the pET39-DsbA:HIV-1Pr plas-
mid and on the production of the chimeric protein was
investigated. Cells grown in 5 different media (each of
them added with 1% (w/v) glucose, see above) at 37°C
were analyzed using the Gompertz equation (Additional
file 1, Figure S2) [18]. The highest amount of cell paste
(about 7.5 g of cells/L culture) was achieved in TB and SB
media. Concerning HIV-1Pr production, protein expres-
sion was induced by adding 1 mM IPTG at cells grown on
different media at the early- or middle-exponential phase
(based on the growth curves as reported in Additional file
1, Figure S2); cell samples were withdrawn up to 3 hours
after induction. Basal expression of recombinant chimeric
HIV-1Pr (i.e., before adding IPTG) was observed only in
SB medium. In all cases, the protein expression increased
with time; the highest levels of DsbA:HIV-1Pr expression
were obtained in TB and M9 medium and collecting the
cells 3 hours after adding IPTG at the middle-exponential
phase of growth (Figure 2).
The effect of medium composition on DsbA:HIV-1Pr
production and the observation that a significant
decrease in pH value was apparent during growth for all
media, with the only exception of TB medium, suggest a
positive role of the buffer system (based on phosphate
salts) for increasing the expression yield. To test this
hypothesis, cultures were grown in LB medium to which
the same concentration of phosphate salts was added as
present in TB or M9 media (~ 70 mM). Western blot
analysis of total cell extracts showed a statistically signif-
icant increase in total DsbA:HIV-1Pr expression in the
presence of phosphate salts, up to 2-fold vs. standard LB
medium (Figure 3B, C).
Figure 2 Western blot analysis of DsbA:HIV-1Pr expression on
total cell extracts of BL21-Codon Plus-(DE3)-RIL E. coli cells
containing the pET39-DsbA:HIV-1Pr plasmid and using
different cultivation media. (Indicated below each panel): the cells
were collected at different times after adding 1 mM IPTG (0, 0.5, 1,
or 3 hours, as indicated above each lane). Protein expression
induced at A) the early-exponential phase, B) the middle-
exponential phase, and C) the stationary phase. An amount of cells
corresponding to 1 mL (panel A) or 0.5 mL (panels B and C) of
culture was loaded in each lane. D) Comparison of DsbA:HIV-1Pr
production level obtained using different growth conditions. The
first bar represents the best conditions identified using different E.
coli strains (see Figure 1). In all cases variability among replicate
cultures was lower than 10%. DsbA:HIV-1Pr expression was detected
using anti-His-tag-specific antibodies. St: 0.5 μg of His-tagged
recombinant D-amino acid oxidase.
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sion and the solubility of heterologous (recombinant)
proteins expressed in E. coli [19]. Thus, the expression
of DsbA:HIV-1Pr in cells grown in TB or M9 medium
at 25, 37, and 42°C after adding IPTG was analyzed
(Figure 4). The temperature did not affect the (in)solubi-
lity of the fusion protein: in all cases most of the
expressed protein accumulated as inclusion bodies.
Indeed, the highest level of total protein expression was
observed growing at 37°C after adding IPTG at the mid-
dle-exponential growth phase.
The aggregated data show that the best conditions for
lab-scale production of DsbA:HIV-1Pr are the use of E.
coli BL21-Codon Plus(DE3)-RIL cells transformed with
the pET39-DsbA:HIV-1Pr plasmid, grown at 37°C in TB
or M9 medium, to which 1% (w/v) glucose has been
added, induced during the middle-exponential phase,
and collected after 3 hours (up to 10 mg of total chi-
meric protein/L).
Purifying DsbA:HIV-1Pr fusion protein
The recombinant DsbA:HIV-1Pr was recovered from
inclusion bodies using a specific solubilization and
refolding procedure. Unsoluble material obtained from
cell disruption was first washed twice with 2 M urea
and 2% (v/v) Triton X-100, followed by a washing step
with the same buffer without urea. Inclusion bodies
were then solubilized using 6 M guanidium chloride
under mild alkaline conditions (pH 8.0) in the presence
of 2-mercaptoethanol as reducing agent and loaded on a
HiTrap Chelating column previously equilibrated in the
same buffer; the presence of 0.5 M NaCl and a low con-
centration of imidazole in the binding buffer reduces
nonspecific interactions with the chromatographic
matrix [20]. The refolded DsbA:HIV-1Pr was eluted,
increasing the imidazole concentration up to 0.5 M.
Lastly, a dialysis protocol comprising three different buf-
fers was set up: at first the pH was decreased (from 8 to
7.5) and imidazole and EDTA concentrations were low-
ered, followed by a further decrease in pH (to 6.8) and
imidazole, EDTA, and NLS concentrations, and finally
equilibrating DsbA:HIV-1Pr in the storage buffer at pH
6.0, containing 5 mM EDTA, 0.01% Triton X-100, 10%
(v/v) glycerol, and 1 mM 2-mercaptoethanol. In order to
avoid precipitation/aggregation of the fusion protein, it
is mandatory to change the pH gradually and to remove
imidazole, EDTA, and NLS: dialysis of solubilized DsbA:
HIV-1Pr against the storage buffer results in loss (preci-
pitation) of a large part of the purified protein. By using
this purification procedure the DsbA:HIV-1Pr fusion
protein can be recovered with a purity grade higher
than 95% (Figure 5A) and a > 80% recovery. Purification
yield was about 8 mg and 6 mg of fusion protein/L cul-
ture for cells grown in TB or M9 media, respectively.
After dialysis, DsbA:HIV-1Pr fusion protein (~ 1 mg/mL)
was digested with two different commercial enterokinases,
as described in Methods section: in both cases full clea-
vage of DsbA:HIV-1Pr was achieved (Figure 5A). Despite
the fact that different chromatographic methods (ion-
exchange, PhenylSepharose, HiTrap chelating, etc.) were
Figure 3 Amount of soluble DsbA:HIV-1Pr and phosphate salts effect on chimeric protein production. A) Comparison by means of
Western blot analysis of the amount of DsbA:HIV-1Pr protein expression in the soluble (S) and insoluble (I) cell fractions as obtained after
disruption of BL21(DE3)pLysS E. coli cells (growth in TB medium, protein expression induced at the early-exponential phase) or of BL21-Codon
Plus-(DE3)-RIL E. coli cells (protein expression induced at the early and middle-exponential phase of growth). B) Western blot analysis of DsbA:
HIV-1Pr protein expression in total cell extracts of recombinant BL21-Codon Plus-(DE3)-RIL E. coli cells grown in the presence of a phosphate salts
buffer system. LB: cells grown in LB medium (control); a: cells grown in LB medium added of 6.78 g/L of NaH2PO4 and 3 g/L of KH2PO4 (such as
in M9 broth); b: cells grown in LB medium to which 9.4 g/L of K2HPO4 and 2.2 g/L of KH2PO4 were added (such as in TB broth). Protein
expression was induced in all samples with 1 mM IPTG; cells were harvested at 1 or 3 hours after adding IPTG. An amount of cells
corresponding to 0.2 mL of culture was loaded in each lane. C) Summary results of DsbA:HIV-1Pr production (see panel B): the expression level
of cells grown on LB medium is reported as 100% (= 1.8 mg/L). Cells were collected at 1 hour (empty bars) and 3 hours (black bars) from IPTG
addition. Western blot analysis was carried out by using anti-His-tag-specific antibodies. St: 0.5 μg of His-tagged recombinant D-amino acid
oxidase.
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separated. The best resolution was achieved by gel-per-
meation chromatography on Superdex 75, reaching a ≤
80% of HIV-1Pr purity and an overall yield of ~2 mg HIV-
1Pr per liter of fermentation broth. The activity of the pur-
ified HIV-1Pr was assayed on substrate III (Bachem),
yielding a specific activity of 1.1 μmol/min mg protein.
Indeed, the purified sample was fully stable at -20°C: no
change in enzymatic activity was observed for up to 6
months.
Expression of GST:HIVPr and HIV-1Pr purification
BL21-CodonPlus(DE3)-RIL E. coli cells transformed with
pGST:HIV or pGST:HIV-His plasmids (see Additional
file 1, Figure S1), grown in LB or TB broth (supplemen-
t e do f1 %g l u c o s e )a t3 7 ° C ,a n dt ow h i c h1m MI P T G
was added at the beginning of the exponential phase of
growth (OD600 nm ~1o r~1 . 8f o rL Bo rT B ,r e s p e c -
tively) produced approx. 0.5 mg of soluble fusion pro-
tein per liter of fermentation broth, corresponding to ~
50% of the overall chimeric protein produced. Soluble
GST:HIVPr and GST:HIVPr-His proteins were purified
from the crude extract on a GSTrap column as
described in the Methods section together with the free
GST protein (see Additional file 1, Figure S3), suggest-
ing an automaturation of the chimeric protein. On the
contrary, when the His-tag was located at the N-term-
inal end of the fusion protein by using the plasmid
pHis-GST:HIV, the His-GST:HIVPr fusion protein was
fully accumulated as inclusion bodies up to ~ 5 mg of
chimeric protein/L fermentation.
By performing the refolding of both GST:HIVPr-His
and His-GST:HIVPr fusion proteins from inclusion
bodies on the HiTrap affinity column (see Methods sec-
tion), ~ 0.7 mg and 5 mg of protein per liter of fermen-
tation could be isolated, respectively. The refolded GST:
HIVPr-His sample contained substantial amounts of
GST protein, exactly as happens for the soluble cellular
fraction (Additional file 1, Figure S3). Indeed, this
enzyme preparation was not cleaved by PreScission pro-
tease (both using the on- or the off-column procedure),
thus preventing the obtainment of pure HIV-1Pr.
Concerning the isolation of HIV-1Pr from the chi-
meric proteins by PreScission protease treatment, the
best result was obtained using the GST:HIVPr or GST:
HIVPr-His soluble forms by on-column cleavage. The
protein eluted in peak 1 of GSTrap column showed a
high degree of purity (≥ 90% as judged by SDS-PAGE,
Figure 5B), while the sample in peak 2 partly coeluted
with the fusion partner GST because of the high HIV-
1Pr hydrophobicity. An overall yield of ≥ 0.15 mg of
pure HIV-1Pr/liter of fermentation broth was achieved
(starting from 0.5 mg of the fused protein/liter). The
activity of the purified HIV-1Pr was assayed on sub-
strate III (Bachem), yielding a specific activity of 1.22
μmol/min mg protein. The Far-UV CD spectrum of the
purified protease showed a ~ 30% b-sheet content (Fig-
ure 5C), as previously reported for folded HIV-1Pr [14].
Conclusions
HIV-1Pr has been prepared by chemical synthesis [2] or
as recombinant protein from E. coli cells, as reported by
Figure 4 Effect of temperature of growth after adding IPTG on the expression of DsbA:HIV-1Pr. Western blot analysis of soluble (S) and
insoluble (I) cell extracts as obtained after disruption of recombinant BL21-Codon Plus-(DE3)-RIL E. coli cells expressing DsbA:HIV-1Pr fusion
protein grown in TB (A) or M9 (B) media at different temperatures. Protein expression was induced by adding 1 mM IPTG at the early or middle-
exponential phase of growth. Experimental conditions as in Figure 2. C) Summary results of soluble (empty bars) vs. insoluble (black bars) level of
DsbA:HIV-1Pr expression in cells induced at the middle-exponential phase of growth and using TB or M9 media (see panels A and B).
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active HIV-1Pr from recombinant E. coli systems has
been relatively low (≤ 1 mg protein/L broth, see Addi-
tional file 1, Table S1) and required complex purification
procedures involving multiple chromatographic steps.
Indeed, the procedures that resulted in higher expression
yields (20-30 mg protein/L) suffered from low reproduci-
bility [11-13]. In order to avoid cell death, overexpressed
HIV-1Pr was also protein encapsulated with an engi-
neered lumazine synthase capsid [21]. The difficulties in
Figure 5 Maturation of HIV-1Pr chimeric proteins by specific protease cleavage and isolation of HIV-1Pr.A )S D S - P A G EA n a l y s i so f
enterokinase maturation of DsbA:HIV-1Pr precursor. B) GSTrap on-column cleavage of GST:HIVPr-His by PreScission protease for 24 hours at 5°C.
Left: elution profile. Peak 1 was eluted in PreScission buffer, after protease cleavage; peak 2 was eluted with 50 mM TrisHCl pH 8.0, 15 mM reduced
L-glutathione. Right: SDS-PAGE analysis of eluted fractions. C) Far-UV CD spectrum of purified mature HIV-1Pr (0.1 mg/mL) in storage buffer.
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by its high commercial cost (~ 25,000 €/mg protein). In
the present paper, we report on a systematic investigation
of HIV-1Pr expression in E. coli based on the combina-
tion of gene design, expression vector, and E. coli strain
selection, and analysis of fermentation broth and condi-
tions. The simple purification and processing procedure
described in this work resulted in the production of ≥ 2
mg of HIV-1Pr/L with a ~ 80% purity following enteroki-
nase digestion of resolubilized DsbA:HIV-1Pr and gel-
permeation chromatography, or ~ 0.15 mg HIV-1Pr/L
with a very high purity degree following PreScission pro-
tease cleavage of soluble GST:HIVPr and GSTrap chro-
matography purification.
In both cases, the purified HIV-1Pr retained its enzy-
matic activity and conformation (see Figure 5C for pure
HIV-1Pr): these protease preparations represent a suita-
ble tool to be employed at the academic level to investi-
gate new strategies to tackle AIDS, i.e., for analyzing the
potentialities of new classes of HIV-1Pr inhibitors [14].
This robust and reliable process for producing HIV-1Pr
at lab-scale can eventually be scaled up to major
volumes.
Methods
Design, synthesis, and cloning of cDNA coding for mature
HIV protease
Synthetic cDNA coding for mature HIV-1Pr was
designed by in silico back translation of the amino acid
sequence reported in the database (GenBank Accession
no. K03455). In order to eliminate autoproteolysis and
to avoid disulfide bridge formation, four substitutions
(Q7K, L33I, L63I and C95A) were inserted in the pri-
mary sequence (see Additional file 1, Figure S1) [15].
Synthetic cDNA was produced by Eurofins Medigen-
omix GmbH (Ebersberg, Germany), after optimizing the
coding nucleotide sequence for expression in E. coli.
The cDNA molecule was cloned into pET24b(+),
pET26b(+), and pET39b(+) expression plasmids (Nova-
gen, Madison, Wisconsin, USA) using NcoI( s i t ei n t r o -
duced by PCR) and XhoI restriction sites. By cloning in
pET39b(+) the target protein can be expressed as a
fusion protein with the E. coli periplasmic protein
dithiol oxidase (DsbA). An additional 6-residue C-term-
inal His-tag encoding sequence is also present in the
resulting pET39-DsbA:HIV-1Pr plasmid.
The HIV-1Pr cDNA was also cloned in pGEX-6P-2
plasmid (GE Healthcare) using BamHI (site introduced
by PCR) and XhoI restriction sites, giving the pGST:HIV
expression vector. Two variants of this plasmid were
further prepared: pGST:HIV-His, obtained using a speci-
fic PCR primer containing the 6-histidine codons before
the XhoI cleavage site, and the pHis-GST:HIV vector
prepared by mutagenesis using pGST:HIV as plasmid
template and the primers HISGST_up (5’- CACACAG-
GAAACAGTATTCATGCATCACCATCACCATCA
CATGTCCCCTATACTAGG -3’)a n dH I S G S T _ d w( 5 ’-
CCTAGTATAGGGGACATGTGATGGTGATGGT
GATGCATGAATACTGTTTCCTGTGTG -3’).
Strain, growth conditions, and enzyme expression
For protein expression, plasmids containing the HIV-1Pr
cDNA were transferred into different E. coli strains:
BL21(DE3)pLysS (Novagen, Madison, Wisconsin, USA),
BL21-Codon Plus(DE3)-RIL (Stratagene, La Jolla, Cali-
fornia, USA), BL21-Star(DE3) (Invitrogen, Carslbad,
California, USA), KRX (Promega, Madison, Wisconsin,
USA), and C41(DE3), C41(DE3)pLysS, C43(DE3), C43
(DE3)pLysS (Lucigen, Middleton, Wisconsin, USA) host
cells. Starter cultures were prepared using a single col-
ony of E. coli cells carrying the recombinant plasmids in
LB medium containing 1% (w/v) glucose and appropri-
ate antibiotics: kanamicin (30 μg/mL final concentra-
tion) and chloramphenicol (34 μg/mL final
concentration, only for BL21-Codon Plus(DE3)-RIL cells
and for pLysS carrying strains) under vigorous shaking
at 37°C. The following media were used [22,23]: Luria-
Bertani (LB, 10 g/L bacto-tryptone, 5 g/L yeast extract,
5 g/L NaCl); Terrific Broth (TB, 12 g/L bacto-tryptone,
24 g/L yeast extract, 8 mL/L glycerol, 2.2 g/L KH2PO4,
9.4 g/L K2HPO4, corresponding to 70 mM total phos-
phate concentration); Super Broth (SB, 32 g/L bacto-
tryptone, 20 g/L yeast extract, 5 g/L NaCl); M9 minimal
medium (0.5 g/L NaCl, 1 g/L NH4Cl, 3 g/L KH2PO4,
6.78 g/L Na2HPO4, corresponding to 68 mM total phos-
phate concentration, 2 mM MgSO4,0 . 1m MC a C l 2,1 0
g/L glucose). Baffled (500 mL) Erlenmeyer flasks con-
taining 100 mL of the different media were inoculated
with the starter culture (initial OD600 nm =0 . 0 5 )a n d
cells were grown at various temperatures with shaking
(180 rpm). Protein expression was induced by adding 1
mM IPTG at different phases of the growth curve, as
indicated in each case. Cells were harvested 30 min, 1
hour, or 3 hours after induction by centrifugation at
8000g for 10 min at 4°C. For protein purification trials,
the cultures were prepared in 2 L Erlenmeyer flasks
containing 700 mL of TB medium, inoculated with the
starter culture (initial OD600 nm = 0.05), and cells grown
at 37°C with shaking (180 rpm). Enzyme expression was
induced by adding 1 mM IPTG at the middle-exponen-
tial phase and cells were harvested as described above 3
hours after adding the inducer. In all cases, cells were
stored at -20°C.
For Dsb:HIV-1Pr purification, crude extracts were pre-
pared by sonication (3-4 cycles of 30 s each, with a 30-s
interval) on ice in 20 mM TrisHCl pH 8.0, 1 mM 2-
mercaptoethanol, 1 mM phenylmethylsulfonylfluoride,
and 10 μg/mL deoxyribonuclease I (3 mL/g cells).
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As concerns the E. coli BL21-CodonPlus(DE3)-RIL cells
transformed with pGST:HIV, pHis-GST:HIV, or pGST:
HIV-His, the soluble fraction containing the fusion pro-
teins was recovered by sonication on ice in PBS pH 7.4
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4), containing 1 mM phenylmethylsulfonyl-
fluoride and 10 μg/mL deoxyribonuclease I (2.5 mL/g
cells). After sonication, 1% (v/v) Triton-X 100 was
added to the sample and it was incubated for 30 min at
4°C with mild shaking. Samples were centrifuged at
34500g for 45 min at 4°C and the soluble fraction
(crude extract) was loaded on a GSTrap column.
Solubilizing and purifying DsbA:HIV-1Pr to remove
inclusion bodies
The insoluble fraction of E. coli cells expressing DsbA:
HIV-1Pr after sonication (containing the inclusion
bodies) was resuspended in 20 mM TrisHCl pH 8.0, 0.5
M NaCl, 2 M urea, and 2% (v/v) Triton X-100 (3 mL/g
cells) and was sonicated (5 cycles of 10 s each, with 30-s
intervals) and centrifuged (34500g for 45 min at 4°C); this
procedure was repeated twice. The pellet was then resus-
pended in 20 mM TrisHCl, pH 8.0, 0.5 M NaCl, and 2%
(v/v) Triton X-100 (3 mL/g cells) and centrifuged as
above. The final pellet (inclusion bodies) was resus-
pended in 20 mM TrisHCl pH 8.0, 0.5 M NaCl, 5 mM
imidazole, 6 M guanidium chloride, and 1 mM 2-mer-
captoethanol (4 mL/g cells) and solubilized by gently
shaking it for 1 hour at room temperature [20]. Samples
were centrifuged at 34500g for 15 min at 4°C. The surna-
tant was filtered through a nonsterile Millex filter (pore
size: 0.45 μm) (Millipore, Bedford, Massachussets, USA)
and loaded on a HiTrap Chelating column (GE Health-
care, Uppsala, Sweden) containing Ni
2+ and equilibrated
in 20 mM TrisHCl pH 8.0, 0.5 M NaCl, 5 mM imidazole,
6 M guanidium chloride, and 1 mM 2-mercaptoethanol.
The column was then extensively washed with the same
buffer and subsequently with 20 mM TrisHCl pH 8.0, 0.5
M NaCl, 20 mM imidazole, 6 M urea, 0.1% (w/v) N-laur-
oyl-sarcosine (NLS), and 1 mM 2-mercaptoethanol. The
fusion protein was then refolded by slowly removing urea
with a linear gradient (from 6 to 0 M) in 30-fold column
volumes, and then eluted from the column using 20 mM
TrisHCl pH 8.0, 0.5 M imidazole, 0.1% (w/v) NLS, 50
mM EDTA, and 5 mM 2-mercaptoethanol [20]. The
eluted protein was dialyzed against the following buffers
(1 hour each): 20 mM TrisHCl pH 7.5, 0.1 M imidazole,
0.1% (w/v) NLS, 20 mM EDTA, 5 mM 2-mercaptoetha-
nol (dialysis buffer 1); 20 mM MES pH 6.8, 10 mM imi-
d a z o l e ,0 . 0 5 %( w / v )N L S ,5m ME D T A ,1m M2 -
mercaptoethanol (dialysis buffer 2); 20 mM MES pH 6.0,
5 mM EDTA, 0.01% (v/v) Triton X-100, 10% (v/v) gly-
cerol, 1 mM 2-mercaptoethanol (storage buffer).
Digestion of DsbA:HIV-1Pr with enterokinase
Two different recombinant enterokinases from bovine
intestine were used: from Sigma-Aldrich (Saint Louis,
Missouri, USA) and from Novagen (Madison, Wiscon-
sin, USA) at 0.02 and 50 U/mg fusion protein, respec-
tively. The digestion reaction was carried out for ~ 16
hours (overnight) at 25°C in storage buffer (see above)
to which 20 μM CaCl2 was added.
Purification of the GST:HIVPr fusion protein and
PreScission protease cleavage
The crude extract containing the various GST:HIVPr
fusion proteins was loaded on a GSTrap column (GE
Healthcare, Uppsala, Sweden) equilibrated in PBS, pH
7.4. The column was then extensively washed with the
same buffer and subsequently equilibrated in PreScission
buffer (50 mM TrisHCl pH 7.5, 10 mM EDTA, 0.15 M
NaCl, and 1 mM 2-mercaptoethanol) for the on-column
cleavage procedure. PreScission protease was then
loaded (70 μLo fa2U / μL solution, GE Healthcare), the
column was immediately closed and incubated for 24
hours at 5°C, followed by 2 hours at room temperature.
The cleaved HIV-1Pr was then eluted in PreScission
buffer.
After loading the crude extract, the GSTrap column
was extensively washed in PBS pH 7.4 and then eluted
with 50 mM TrisHCl pH 8.0 containing 15 mM reduced
L-glutathione (Sigma Aldrich) for off-column PreScis-
sion protease cleavage (see above). The fusion protein
was extensively dialyzed against PreScission buffer at 4°
C, and then added of PreScission protease (20 U per mg
of fusion protein). After incubation for 24 hours at 5°C
followed by 2 hours at room temperature, the sample
was loaded on a GSTrap column equilibrated in PreScis-
sion buffer, following the procedures described above.
The eluted protein was dialyzed against the following
buffers (1 hour each): 20 mM MES pH 6.8, 5 mM
EDTA, 0.01% (v/v) Triton-X 100, 5% (v/v) glycerol, 1
mM 2-mercaptoethanol; 20 mM MES pH 6.0, 5 mM
EDTA, 0.01% (v/v) Triton X-100, 10% (v/v) glycerol, 1
mM 2-mercaptoethanol (storage buffer).
SDS-PAGE Electrophoresis and Western blot analysis
Proteins from total cell extract or from both soluble and
insoluble cell fractions were separated by SDS-PAGE.
For total cell extracts and for insoluble fractions after
cell disruption, cell pellets were directly resuspended in
an appropriate volume of Laemmli sample buffer. For
Western blot analysis, proteins were transferred electro-
phoretically onto a nitrocellulose membrane and the
fusion protein was detected using anti-His-tag mouse
monoclonal antibodies (His-probe, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and goat anti-mouse IgG
HRP-conjugated antibodies (Santa Cruz Biotechnology,
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strated by a chemiluminescence method (ECL Plus Wes-
tern Blotting Detection System, GE Healthcare, Uppsala,
Sweden). His-Tagged D-amino acid oxidase was used as
positive control [24].
HIV-1Pr Activity assay and CD measurements
A chromogenic substrate for HIV protease (substrate III,
Bachem, Switzerland; with sequence H-His-Lys-Ala-Arg-
Val-Leu-Phe(NO2)-Phe-Glu-Ala-Nle-Ser-NH2)w a sd i s -
solved in 100% DMSO to reach a concentration of 10
mg/mL. The assay was performed in 20 mM sodium
phosphate pH 6.0, 0.8 mM NaCl, 1 mM EDTA, and 1
mM dithiothreitol (freshly added). Each measurement
was performed by recording the absorbance at 310 nm
with a Jasco V-560 spectrophotometer, at 25°C, using
cuvettes with a 3-mm optical path. The total volume
sample was 70 μL; activity was assayed on a 100 μM
substrate with a 10% DMSO final concentration. HIV-
1Pr specific activity was calculated using the substrate
extinction coefficient 500 M
-1 cm
-1, as reported in [14].
Far-UV CD spectra were recorded in a Jasco J-815
spectrometer at 0.1 mg protein/mL and in storage buf-
fer, as detailed in [25].
Additional material
Additional File 1: Supplementary HIV-1Pr.PDF. Supplementary text
describes the expression trials using pET24b(+) or pET26b(+) plasmid.
Figure S1 describes the amino acid sequence of the chimeric proteins
and the mature HIV-1Pr used in this work. Figure S2 reports the growth
curve of BL21-Codon Plus-(DE3)-RIL E. coli cells carrying the pET39-DsbA:
HIV-1Pr plasmid in different media. Figure S3 reports the SDS-PAGE
analysis of the purification of GST:HIV-1Pr protease fusion forms. Table S1
summarizes published results concerning the production of recombinant
HIV-1Pr in different heterologous hosts.
List of abbreviations
DsbA: periplasmic E. coli dithiol oxidase; HIV-1Pr: aspartyl-protease encoded
by HIV; IPTG: isopropyl-β-D-thiogalactopyranoside; NLS: N-lauroyl-sarcosine;
GST: glutathione S-transferase.
Acknowledgements
This work was supported by grants from Fondo di Ateneo per la Ricerca to
L. Pollegioni and L. Piubelli. We thank the support from Consorzio
Interuniversitario per le Biotecnologie (CIB) and Centro di Ricerca in
Biotecnologie per la Salute Umana. We are grateful to Gianluca Molla for the
gene design and to Flavia Marinelli for helpful discussion.
Author details
1Dipartimento di Biotecnologie e Scienze Molecolari, Università degli Studi
dell’Insubria, via J.H. Dunant 3, Varese, 21100, Italy.
2The Protein Factory,
Centro Interuniversitario di Ricerca in Biotecnologie Proteiche, Politecnico di
Milano and Università degli Studi dell’Insubria, via Mancinelli 7, Milano,
20131, Italy.
Authors’ contributions
LP conceived the project and wrote the paper. FV produced the expression
plasmids, performed the overexpression trials, purified HIV-1Pr from DsbA:
HIV-1Pr and GST:HIVPr precursors, analyzed the data and helped write the
paper. LuPi performed expression experiments on the DsbA:HIV-1Pr, purified
HIV-1Pr from the fusion partner, and helped write the paper. All authors
have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2011 Accepted: 30 June 2011
Published: 30 June 2011
References
1. Hill M, Tachedjian G, Mak J: The packaging and maturation of the HIV-1
Pol proteins. Curr HIV Res 2005, 3:73-85.
2. Nutt RF, Brady SF, Darke PL, Ciccarone TM, Colton CD, Nutt EM, Rodkey JA,
Bennett CD, Waxman LH, Sigal IS, Anderson PS, Veber DF: Chemical
synthesis and enzymatic activity of a 99-residue peptide with a
sequence proposed for the human immunodeficiency virus protease.
Proc Natl Acad Sci USA 1988, 85:7129-7133.
3. Hui JO, Tomasselli AG, Reardon IM, Lull JM, Brunner DP, Tomich C-SC,
Heinrikson RL: Large scale purification and refolding of HIV-1 protease
from Escherichia coli inclusion bodies. J Protein Chem 1993, 12:323-327.
4. Hansen J, Billich S, Schulze T, Sukrow S, Moelling K: Partial purification and
substrate analysis of bacterially expressed HIV protease by means of
monoclonal antibody. EMBO J 1988, 7:1785-1791.
5. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B: Overexpression
of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-
1 protease and inhibition of assembly and budding of virus-like
particles. Virology 1993, 193:661-671.
6. Rizzo CJ, Korant BD: Genetic approaches designed to minimize
cytotoxicity of retroviral protease. Methods Enzymol 1994, 241:16-29.
7. Wan M, Takagi M, Loh BN, Imanaka T: Comparison of HIV-1 protease
expression in different fusion forms. Biochem Mol Biol Int 1995,
36:411-419.
8. Dergousova NI, Amerik AY, Volynskaya AM, Rumsh LD: HIV-I protease.
Cloning, expression, and purification. Appl Biochem Biotech 1996,
61:97-107.
9. Leuthardt A, Roesel JL: Cloning, expression and purification of a
recombinant poly-histidine-linked HIV-1 protease. FEBS Lett 1993,
326:275-280.
10. Olins PO, Lee SC: Recent advances in heterologous gene expression in
Escherichia coli. Curr Opin Biotechnol 1993, 4:520-525.
11. Komai T, Ishikawa Y, Yagi R, Suzuki-Sunagawa H, Nishigaki T, Handa H:
Development of HIV-1 protease expression methods using the T7 phage
promoter system. Appl Microbiol Biotechnol 1997, 47:241-245.
12. Cheng YS, McGowan MH, Kettner CA, Schloss JV, Erickson-Viitanen S,
Yin FH: High-level synthesis of recombinant HIV-1 protease and the
recovery of active enzyme from inclusion bodies. Gene 1990, 87:243-248.
13. Gustafson ME, Junger KD, Foy BA, Baez JA, Bishop BF, Rangwala SH,
Michener ML, Leimgruber RM, Houseman KA, Mueller RA, Matthews BK,
Olins PO, Grabner RW, Hershman A: Large-scale production of HIV-1
protease from Escherichia coli using selective extraction and membrane
fractionation. Protein Expr Purif 1995, 6:512-518.
14. Broglia RA, Provasi D, Vasile F, Ottolina G, Longhi R, Tiana G: A folding
inhibitor of the HIV-1 protease. Proteins 2006, 62:928-933.
15. Louis JM, Clore GM, Gronenborn AM: Autoprocessing of HIV-1 protease is
tightly coupled to protein folding. Nature Struct Biol 1999, 6:868-875.
16. Egan SM, Schleif RF: A regulatory cascade in the induction of rhaBAD. J
Mol Biol 1993, 234:87-98.
17. Haldimann A, Daniels L, Wanner B: Use of new methods for construction
of tightly regulated arabinose and rhamnose promoter fusions in
studies of the Escherichia coli phosphate regulon. J Bacteriol 1998,
180:1277-1286.
18. Zwietering MH, Jongenburger I, Rombouts FM, van’t Riet K: Modeling of
the bacterial growth curve. Appl Environ Microbiol 1990, 56:1875-1881.
19. Schein CH: Production of soluble recombinant proteins in bacteria.
BioTechnology 1989, 7:1141-1148.
20. Molla G, Bernasconi MG, Sacchi S, Pilone MS, Pollegioni L: Expression in
Escherichia coli and in vitro refolding of the human protein pLG72.
Protein Expr Purif 2006, 46:150-155.
21. Worsdorfer B, Woycechowsky KJ, Hilverd D: Directed evolution of a
protein container. Science 2011, 331:589-592.
Volontè et al. Microbial Cell Factories 2011, 10:53
http://www.microbialcellfactories.com/content/10/1/53
Page 9 of 1022. Volontè F, Marinelli F, Gastaldo G, Sacchi S, Pilone MS, Pollegioni L, Molla G:
Optimization of glutaryl-7-aminocephalosporanic acid acylase expression
in E. coli. Prot Express Purif 2008, 61:131-137.
23. Volontè F, Pollegioni L, Molla G, Frattini L, Marinelli F, Piubelli L: Production
of recombinant cholesterol oxidase containing covalently bound FAD in
Escherichia coli. BMC Biotech 2010, 10:33.
24. Fantinato S, Pollegioni L, Pilone MS: Engineering, expression and
purification of a His-tagged chimeric D-amino acid oxidase from
Rhodotorula gracilis. Enzyme Microb Technol 2005, 29:407-412.
25. Caldinelli L, Iametti S, Barbiroli A, Bonomi F, Fessas D, Molla G, Pilone MS,
Pollegioni L: Dissecting the structural determinants of the stability of
cholesterol oxidase containing covalently bound flavin. J Biol Chem 2005,
280:22572-22581.
doi:10.1186/1475-2859-10-53
Cite this article as: Volontè et al.: Optimizing HIV-1 protease production
in Escherichia coli as fusion protein. Microbial Cell Factories 2011 10:53.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Volontè et al. Microbial Cell Factories 2011, 10:53
http://www.microbialcellfactories.com/content/10/1/53
Page 10 of 10